+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030- Product Image
Respiratory Disease Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030- Product Image
Sale

Respiratory Disease Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012369
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Vaccine Market grew from USD 24.78 billion in 2024 to USD 26.28 billion in 2025. It is expected to continue growing at a CAGR of 5.89%, reaching USD 34.95 billion by 2030.

Shaping Tomorrow’s Respiratory Vaccine Market

The global landscape for respiratory disease vaccines stands at an inflection point, driven by scientific breakthroughs, evolving regulatory frameworks, and shifting public health priorities. As pathogens adapt and new variants emerge, vaccine developers and public health authorities confront unparalleled urgency to innovate and distribute effective immunization solutions. This executive summary distills critical insights into the current market environment, elucidating the forces reshaping product development, regulatory compliance, and distribution strategies.

By tracing the arc from foundational research to end-user delivery, this analysis offers decision-makers a clear view of the mechanisms that underpin success in this high-stakes arena. It balances granular examination of vaccine modalities and demographic considerations with a holistic understanding of geopolitics and trade dynamics. Ultimately, the goal is to equip stakeholders-ranging from biotech pioneers to national immunization programs-with the foresight and context needed to navigate complexity, mitigate risk, and accelerate the deployment of life-saving vaccines.

Landmark Innovations Redefine Preventive Medicine

Innovation has never been more pivotal in the fight against respiratory pathogens. Conjugate and subunit vaccines have built upon decades of immunological research, while mRNA platforms have propelled the field into a new dimension of adaptability and speed. Live attenuated and inactivated vaccines continue to offer proven safety profiles, even as viral vector approaches unlock the potential for multivalent formulations. These technological advances are complemented by refined cold-chain solutions and novel adjuvant systems, enabling targeted immunogenicity across vulnerable populations.

Simultaneously, regulatory agencies worldwide are streamlining approval pathways, catalyzing a shift from rigid trial paradigms to adaptive designs that can respond to emergent variants. Public-private partnerships are proliferating, harnessing collective resources to accelerate scale-up. As a result, the once-linear roadmap from discovery to distribution is evolving into a dynamic ecosystem where cross-sector collaboration and real-time data exchange drive continuous improvement and enhanced global preparedness.

Tariff Dynamics Redraw Competitive Boundaries

In 2025, newly imposed tariffs have introduced a complex overlay onto the respiratory vaccine supply chain, altering cost structures and sourcing decisions. Duties on key raw materials have elevated the importance of local manufacturing capabilities, prompting many stakeholders to reassess offshore dependencies. Vaccine developers and contract manufacturers are exploring strategic partnerships within the United States to mitigate exposure to import levies, fostering capacity expansion in domestic bioreactors, fill-and-finish facilities, and cold storage infrastructure.

These trade measures have also influenced procurement strategies among government immunization programs. Bulk purchasing contracts are increasingly factoring in total landed costs, shifting the competitive landscape in favor of manufacturers with vertically integrated operations. While tariffs present short-term margin pressures, they simultaneously drive investment in resilience and supply chain transparency, ultimately strengthening the ecosystem’s ability to adapt to future disruptions.

Unveiling the Market’s Multifaceted Segments

The respiratory disease vaccine market can be dissected through a multifaceted lens that reveals distinct pathways for growth and specialization. When analyzing by vaccine type, the established safety record of inactivated and live attenuated platforms coexists with the rapid adaptability of mRNA technology, and the targeted precision of conjugate, subunit, and viral vector formulations. Each modality aligns with unique logistical requirements, from cold-chain complexity to production scale, creating differentiated opportunities for manufacturers.

Demographic considerations further refine market segmentation. Adult immunization programs span young adults seeking preventive boosters, middle-aged individuals facing occupational exposure, and older adults with compounding comorbidities. Geriatric categories distinguish between seniors and the elderly, both requiring tailored immunogenic profiles and dosage schedules. Pediatric strategies encompass infants whose immune systems demand carefully calibrated attenuated or subunit approaches, children and adolescents with school-based distribution imperatives, and toddlers benefiting from minimally invasive administration routes.

Distribution channels represent another critical dimension. Direct purchase arrangements with government and institutional buyers contrast with hospital pharmacy deployments that leverage inpatient networks. Online pharmacies-via mobile app sales and website portals-have surged in popularity, complementing traditional retail pharmacy models segmented into chain and independent outlets. End users range from clinics and home care services, which prioritize ease of administration and simplified storage, to hospitals-both government-run and privately managed-that demand high-volume, stringent compliance solutions. Research institutes round out the landscape, driving early-stage trials and combination therapy exploration.

Finally, the method of administration shapes both patient experience and supply chain considerations. Intramuscular injections remain the cornerstone for systemic immunity, while intranasal delivery offers mucosal protection. Oral vaccines underscore the promise of needle-free platforms, enhancing uptake among pediatric populations. Subcutaneous formulations provide flexibility for home-based administration and self-care regimens. Together, these interlocking segments paint a comprehensive portrait of where innovation meets real-world application.

Regional Footprints Illuminate Growth Trajectories

Geographic dynamics impart an equally compelling narrative of opportunity and challenge. In the Americas, robust public health infrastructures and significant government investment drive demand for both established and next-generation vaccine technologies. North American markets benefit from advanced manufacturing ecosystems, while Latin American countries increasingly emphasize local capacity building to reduce reliance on external sources.

Across Europe, the Middle East, and Africa, strategic alliances and regional procurement mechanisms are accelerating cross-border distribution. European nations leverage harmonized regulatory frameworks to streamline approvals, whereas Middle East initiatives focus on pandemic preparedness and stockpile management. In Africa, ongoing efforts to expand cold chain networks and enhance clinical trial capabilities are key to unlocking broader immunization coverage.

Asia-Pacific stands out for its manufacturing scale and cost efficiencies, with major biopharmaceutical hubs in East and South Asia supplying both regional and global markets. Public-private partnerships in this region are pioneering innovative delivery models, including mobile vaccination clinics and digital health platforms. Concurrently, emerging economies are prioritizing equitable access, integrating respiratory vaccines into national immunization schedules, and strengthening surveillance systems.

Industry Titans Steer Vaccine Evolution

The competitive arena features a diverse array of stakeholders ranging from established pharmaceutical giants to agile biotech disruptors. Long-standing players with extensive portfolios in conjugate and inactivated vaccines are leveraging their global distribution networks to reinforce market share. Meanwhile, mRNA pioneers have attracted unprecedented investment, rapidly scaling production capacities and forming strategic alliances with contract development and manufacturing organizations.

Emerging biotech firms specializing in subunit, viral vector, and novel adjuvant platforms are carving out niche positions, often by targeting specific demographic or geographic segments underserved by mainstream solutions. Contract research organizations and fill-and-finish specialists are strategically aligning with these innovators, facilitating accelerated time-to-market. Regulatory consultants, logistics providers, and digital health companies are also gaining prominence by offering integrated, end-to-end services that span the preclinical pipeline through to post-market surveillance.

Strategic Imperatives for Market Leadership

To capitalize on the evolving respiratory vaccine landscape, industry leaders should prioritize the development of flexible manufacturing platforms that can pivot swiftly between modalities and dosages. Strengthening domestic supply chains through strategic partnerships and localized production will offset tariff-related risks and ensure continuity of supply. Integrating real-time data analytics into clinical and operational workflows will expedite regulatory submissions and enhance batch-to-batch consistency.

From a commercial standpoint, tailored outreach to distinct demographic cohorts-leveraging digital engagement tools and community-based initiatives-will bolster uptake rates. Collaborating with government agencies to co-design immunization programs can unlock favorable procurement terms and public trust. Additionally, investing in cold chain innovation and decentralized administration models will expand accessibility, particularly in remote or resource-constrained settings.

Methodical Blueprint Underpinning Our Insights

This analysis draws upon a rigorous, multi-pronged research framework combining primary interviews with leading vaccine developers, regulatory affairs specialists, and distribution experts. Secondary data sources encompass regulatory filings, peer-reviewed literature, and proprietary databases tracking clinical trials, patent filings, and manufacturing trends. Substantive cross-validation ensures that insights reflect both macroeconomic dynamics and granular operational realities.

Quantitative assessments of tariff impacts and supply chain resilience were complemented by qualitative scenario planning, exploring potential shifts in public health policy and technological adoption. Geographic analyses incorporated regional health expenditure data, demographic projections, and infrastructure assessments. Throughout, a disciplined peer-review process with subject-matter experts fortified the objectivity and relevance of our conclusions.

Closing Perspectives on Vaccine Frontiers

As respiratory disease vaccines continue to serve as a cornerstone of global health security, the confluence of technological innovation, regulatory evolution, and trade policy will determine which organizations thrive. The nuanced interplay of vaccine modalities, demographic needs, distribution channels, regional strategies, and tariff environments demands a cohesive, forward-looking approach. Success will hinge on the ability to integrate scientific excellence with adaptive supply chain design, stakeholder collaboration, and data-driven decision-making.

By synthesizing these dimensions, this executive summary offers a strategic vantage point, empowering leaders to navigate uncertainty and drive meaningful impact. The path ahead is challenging, but those who embrace agility, partnership, and innovation are poised to deliver transformative health outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Conjugate Vaccine
    • Inactivated Vaccine
    • Live Attenuated Vaccine
    • MRNA Vaccine
    • Subunit Vaccine
    • Viral Vector Vaccine
  • Age Group
    • Adult
      • Middle Aged
      • Older Adult
      • Young Adult
    • Geriatric
      • Elderly
      • Senior
    • Pediatric
      • Adolescent
      • Child
      • Infant
      • Toddler
  • Distribution Channel
    • Direct Purchase
    • Hospital Pharmacy
    • Online Pharmacy
      • Mobile App Sales
      • Website Sales
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Clinics
    • Home Care
    • Hospitals
      • Government Hospitals
      • Private Hospitals
    • Research Institutes
  • Route Of Administration
    • Intramuscular
    • Intranasal
    • Oral
    • Subcutaneous
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Seqirus Pty Ltd
  • Moderna, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Novavax, Inc.
  • BioNTech SE
  • Sinovac Biotech Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Disease Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. Conjugate Vaccine
8.3. Inactivated Vaccine
8.4. Live Attenuated Vaccine
8.5. MRNA Vaccine
8.6. Subunit Vaccine
8.7. Viral Vector Vaccine
9. Respiratory Disease Vaccine Market, by Age Group
9.1. Introduction
9.2. Adult
9.2.1. Middle Aged
9.2.2. Older Adult
9.2.3. Young Adult
9.3. Geriatric
9.3.1. Elderly
9.3.2. Senior
9.4. Pediatric
9.4.1. Adolescent
9.4.2. Child
9.4.3. Infant
9.4.4. Toddler
10. Respiratory Disease Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Direct Purchase
10.3. Hospital Pharmacy
10.4. Online Pharmacy
10.4.1. Mobile App Sales
10.4.2. Website Sales
10.5. Retail Pharmacy
10.5.1. Chain Pharmacy
10.5.2. Independent Pharmacy
11. Respiratory Disease Vaccine Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
11.4.1. Government Hospitals
11.4.2. Private Hospitals
11.5. Research Institutes
12. Respiratory Disease Vaccine Market, by Route Of Administration
12.1. Introduction
12.2. Intramuscular
12.3. Intranasal
12.4. Oral
12.5. Subcutaneous
13. Americas Respiratory Disease Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Respiratory Disease Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Respiratory Disease Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi S.A.
16.3.4. Seqirus Pty Ltd
16.3.5. Moderna, Inc.
16.3.6. AstraZeneca plc
16.3.7. Johnson & Johnson
16.3.8. Novavax, Inc.
16.3.9. BioNTech SE
16.3.10. Sinovac Biotech Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RESPIRATORY DISEASE VACCINE MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY DISEASE VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY DISEASE VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 80. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 81. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 82. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 84. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 85. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 145. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 147. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 148. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 149. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 151. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 152. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 156. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 158. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 159. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 160. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 163. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 178. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 180. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 181. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 182. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 184. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 185. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 189. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 191. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 192. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 193. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 195. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 196. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 233. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 235. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 236. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 237. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 239. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 251. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 255. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 257. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 258. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 259. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 262. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 266. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 268. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 269. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 270. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 273. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 284. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 299. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 301. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 302. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 303. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 305. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 306. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 308. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 310. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 311. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 312. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 313. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 314. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 316. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 317. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TAB

Companies Mentioned

The companies profiled in this Respiratory Disease Vaccine market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Seqirus Pty Ltd
  • Moderna, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Novavax, Inc.
  • BioNTech SE
  • Sinovac Biotech Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.95 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Respiratory Disease Vaccines - Global Strategic Business Report - Product Image

Respiratory Disease Vaccines - Global Strategic Business Report

  • Report
  • 73 Pages
  • Global
From
Respiratory Disease Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Respiratory Disease Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Respiratory Disease Vaccine Market Report 2025 - Product Image

Respiratory Disease Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Swine Epidemic Encephalitis Inactivated Vaccine Market by Animal Classification, Vaccine Type, Dosage Form, Packaging Size, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Swine Epidemic Encephalitis Inactivated Vaccine Market by Animal Classification, Vaccine Type, Dosage Form, Packaging Size, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From

About the Respiratory Disease Vaccine Market

The Respiratory Disease Vaccine market is a subset of the larger Respiratory Drugs market. Vaccines are used to prevent the spread of respiratory diseases, such as influenza, pneumonia, and tuberculosis. Vaccines are typically administered to children and adults, and are often recommended for those at high risk of developing respiratory diseases. Vaccines are typically administered through injection, nasal spray, or oral drops. The Respiratory Disease Vaccine market is highly competitive, with many companies offering a variety of vaccines. Companies in the market include Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. These companies are involved in the research, development, and production of vaccines for a variety of respiratory diseases. Additionally, many of these companies are involved in the distribution of vaccines to healthcare providers and pharmacies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.